Case report: Successful management of a refractory double-expressor diffuse large B-cell lymphoma patient under the guidance of in vitro high-throughput drug sensitivity test

INTRODUCTION: Double-expressor diffuse large B-cell lymphoma (DEL), harboring double expression of MYC and BCL2, has an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). We initiated a clinical trial to tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Lijie, Wang, Hui, Liu, Dan, He, Qiang, Li, Zengjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890053/
https://www.ncbi.nlm.nih.gov/pubmed/36741708
http://dx.doi.org/10.3389/fonc.2022.1079890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890053/
https://www.ncbi.nlm.nih.gov/pubmed/36741708
http://dx.doi.org/10.3389/fonc.2022.1079890

Ejemplares similares